By Turna Ray

NEW YORK (GenomeWeb News) – How broad can the claims in a gene patent be without impeding research and still be of financial value to the patent holder? While a US District Court judge in a pending high-profile anti-gene patenting case is currently mulling over the answer to this very question, researchers from Duke University used bioinformatics to estimate the reach of a claim from one of Myriad Genetics' patents on the BRCA1 gene.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.